Kindstar Globalgene finds bargain in solid tumor testing acquisition
The testing services provider’s proposed $31.3 million purchase price for AnchorDx represents a heavy discount to the company’s earlier valuations Key Takeaways: Kindstar Globalgene’s proposed acquisition of AnchorDx would allow…
Recent Articles
RELATED ARTICLES
-
CHINA BULLETIN: Manufacturing Déjà Vu
-
Sinking Burning Rock faces de-listing. But could privatization bid come first?
BNR.US
- CHINA BULLETIN: Services, Trade Send Positive Signals
- Saimo Tech revs up for another IPO race after two false starts
- Payment app Lianlian seeks IPO relief from cash crunch
- CHINA BULLETIN: Fiscal Revenue, Land Sales Fall in April
- CHINA BULLETIN: Factories Send Mixed Signals
